Article
Efficacy of crisugabalin (HSK16149) for refractory chronic cough: study protocol for a randomized, double-blind, placebo-controlled trial
2026-08-12
Abstract excerpt
<title>Abstract</title> <p>Background: Refractory chronic cough (RCC) persists despite systematic evaluation showing no clear cause, or despite adequate treatment of an identified or strongly suspected cause. RCC remains difficult to treat. Although gabapentinoids can reduce cough and improve quality of life, their benefits may be limited by slow onset, central nervous system adverse effects, and relapse after di...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 98717ede-379f-5fa3-a393-7b3af00070fb
- DOI
- 10.21203/rs.3.rs-8997408/v1
